100706-药理学

抗肿瘤药物药理

1996-09--2001-07   中科院上海药物研究所   理学博士
1992-09--1996-09   华东师范大学   理学学士

   

2006-03~现在, 中科院上海药物研究所, 副研究员，研究员
2001-09~2006-03,美国国立癌症研究所, 博士后
1996-09~2001-07,中科院上海药物研究所, 理学博士
1992-09~1996-09,华东师范大学, 理学学士

2023-03-01-2026-02-28,上海市抗癌协会, 理事
2022-12-01-2026-11-30,上海市药理学会, 理事
2012-12-01-今,Acta Pharmacologica Sinica 编委, 编委
2007-07-01-今,中国药理学会肿瘤药理专业委员会, 委员
2007-06-29-今,中国抗癌协会抗癌药物专业委员会, 委员

   

（1） 2023年度浦东新区“明珠工程师, 市地级, 2023

（ 1 ） 含杂环侧链的噁二唑衍生物、合成方法及其应用, 2019, 第 2 作者, 专利号: CN110143955A

（ 2 ） 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途, 2019, 第 2 作者, 专利号: CN109111447A

（ 3 ） 去氮嘌呤类化合物及其药物组合物、制备方法和用途, 2018, 第 2 作者, 专利号: CN107722013A

（ 4 ） 蛋白激酶抑制剂, 2017, 第 3 作者, 专利号: CN107207441A

（ 5 ） 一类取代喹唑啉-4-酮类化合物及其制备方法和医药用途, 2017, 第 2 作者, 专利号: CN106995438A

（ 6 ） 双环稠杂环化合物及其用途和药物组合物, 2014, 第 3 作者, 专利号: CN103626783A

（ 7 ） 一类吡唑并吡啶类化合物及其制备方法、用途和药物组合物, 2014, 第 3 作者, 专利号: CN103570709A

（ 8 ） 吡咯2,1-f1,2,4并三嗪类化合物,其制备方法及用途, 2013, 第 2 作者, 专利号: CN103450204A

（ 9 ） 一类三嗪类化合物、该化合物的制备方法及其用途, 2013, 第 4 作者, 专利号: CN102887867A

（ 10 ） 一类噻唑类化合物及其制备方法和用途, 2012, 第 8 作者, 专利号: CN102775368A

（ 11 ） 一种检测化合物对人Ⅰ型PI3Ks抑制活性的方法, 2012, 第 1 作者, 专利号: CN102719517A

（ 12 ） 一类吲唑类化合物及其制备方法、用途和药物组合物, 2012, 第 2 作者, 专利号: CN102675286A

（ 13 ） 一种对映-贝壳杉烷型二萜及其衍生物和制备方法, 2012, 第 5 作者, 专利号: CN102584760A

（ 14 ） 吡啶并吡咯三嗪化合物、其制备方法和用途, 2012, 第 2 作者, 专利号: CN102558185A

（ 15 ） 菲并吲哚里西啶生物碱衍生物及其盐和抗癌活性, 2011, 第 2 作者, 专利号: CN102002041A

（ 16 ） 一类新型苯并蒽环类化合物及其制备方法和用途, 2011, 第 2 作者, 专利号: CN101993446A

（ 17 ） 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途, 2010, 第 5 作者, 专利号: CN101676291A

   

（1） Discovery of Pyrido[2,3- d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment., J Med Chem, 2024, 
（2） Second messenger 2'3'-cyclic GMP-AMP (2'3'-cGAMP): the cell autonomous and non-autonomous roles in cancer progression., Acta Pharmacol Sin, 2024, 
（3） Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3K�� inhibitors., Signal Transduct Target Ther, 2023, 
（4） Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation, Int J Biol Sci, 2023, 
（5） Targeting PI3K�� overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R, Acta Pharmacol Sin, 2023, 
（6） Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy, Acta Pharmaceutica Sinica B, 2022, 
（7） Repressing MYC by targeting BET synergizes with selective inhibition of PI3K�� against B cell lymphoma, Cancer Lett., 2022, 
（8） Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3K�� inhibitors in esophageal squamous cell carcinoma, Clin Transl Med, 2022, 
（9） SAF-248, a novel PI3K delta-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma, ACTA PHARMACOLOGICA SINICA, 2021, 第 14 作者  通讯作者
（10） 多靶点抗肿瘤天然产物研究进展, Research progress in multi-targeted anti-tumor natural products, 药学学报, 2021, 第 2 作者
（11） PI3K�� inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8 + T cells and promoting fatty acid metabolism, J Immunother Cancer, 2021, 
（12） Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead., Gene & Diseases, 2021, 
（13） Adaptive resistance to PI3K alpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells, CELL DEATH & DISEASE, 2021, 第 12 作者  通讯作者
（14） PI3K alpha inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma, SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 第 5 作者
（15） Corrigendum to "Systematic combination screening reveals synergism between rapamycin and sutent against human lung cancer" Cancer Letter 342(2014) 159-166, CANCER LETTERS, 2020, 第 4 作者
（16） 源于天然产物或其衍生物的分子靶向抗肿瘤药物研究进展, Progress in molecularly targeted anti-tumor drugs derived from natural products or their derivatives, 药学学报, 2020, 第 2 作者
（17） CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment, crisprcas9apowerfultooltowardsprecisionmedicineincancertreatment, ACTA PHARMACOLOGICA SINICA, 2020, 第 2 作者  通讯作者
（18） Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo2,1-f1,2,4triazine derivatives, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 第 6 作者  通讯作者
（19） Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 第 6 作者  通讯作者
（20） Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening, Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening, ACTA PHARMACOLOGICA SINICA, 2020, 第 8 作者  通讯作者
（21） Systematic combination screening reveals synergism between rapamycin and sutent against human lung cancer (vol 342, pg 159, 2014), CANCER LETTERS, 2020, 第 4 作者  通讯作者
（22） Simultaneous inhibition of PI3K alpha and CDK4/6 synergistically suppresses Kras-mutated non-small cell lung cancer, MOLECULAR CANCER RESEARCH, 2020, 第 8 作者
（23） Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho -Naphthaquinone-Containing Natural Product, MOLECULES, 2019, 第 6 作者  通讯作者
（24） Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3K alpha inhibition in breast cancer, SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 第 10 作者  通讯作者
（25） Design, synthesis, and biological evaluation of thieno3,2-dpyrimidine derivatives as potential simplified phosphatidylinositol 3-kinase alpha inhibitors, CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 第 7 作者  通讯作者
（26） Simultaneous inhibition of PI3K alpha and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer, CANCER BIOLOGY & MEDICINE, 2019, 第 12 作者  通讯作者
（27） Design, synthesis, and biological activity evaluation of (-)-6-O-desmethylantofine analogues as potent anti-cancer agents, BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 第 9 作者  通讯作者
（28） HRAS(G12s) mutant mediates resistance to a PI3K alpha inhibitor CYH33 in esophageal squamous cell carcinomas, MOLECULAR CANCER THERAPEUTICS, 2019, 第 9 作者
（29） Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA(H1047R) accompanied with pro-tumorigenic secretome, INTERNATIONAL JOURNAL OF CANCER, 2019, 第 9 作者  通讯作者
（30） Simultaneous inhibition of PI3K�� and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer, CANCER BIOLOGY AND MEDICINE, 2019, 第 12 作者
（31） PI3K alpha inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment, CANCER LETTERS, 2019, 第 8 作者  通讯作者
（32） Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer, simultaneousinhibitionofpi3kandcdk46synergisticallysuppresseskrasmutatednonsmallcelllungcancer, 癌症生物学与医学:英文版, 2019, 第 12 作者
（33） Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K alpha-selective inhibitor CYH33 in breast cancer, CANCER LETTERS, 2018, 第 16 作者  通讯作者
（34） Discovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo2,1-f1,2,4triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors, CANCER RESEARCH, 2018, 第 9 作者
（35） Oncogene-induced senescence: a double edged sword in cancer, ACTA PHARMACOLOGICA SINICA, 2018, 第 3 作者  通讯作者
（36） The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8, ACTA PHARMACOLOGICA SINICA, 2018, 第 6 作者  通讯作者
（37） Oncogene-induced senescence: a double edged sword in cancer, Oncogene-induced senescence: a double edged sword in cancer, 中国药理学报：英文版, 2018, 第 3 作者
（38） Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf V600E inhibitors, ACTA PHARMACOLOGICA SINICA, 2017, 第 9 作者  通讯作者
（39） Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K alpha-selective Inhibitors in Breast Cancer, THERANOSTICS, 2017, 第 9 作者  通讯作者
（40） Discovery of a Novel Series of 7-AzaindoleScaffold Derivatives as PI3K Inhibitors with Potent Activity, ACS MEDICINAL CHEMISTRY LETTERS, 2017, 第 9 作者  通讯作者
（41） 6-OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression, JOURNAL OF MEDICINAL CHEMISTRY, 2017, 第 10 作者  通讯作者
（42） New Insights into PI3K Inhibitor Design using X-ray Structures of PI3K alpha Complexed with a Potent Lead Compound, SCIENTIFIC REPORTS, 2017, 第 7 作者  通讯作者
（43） Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond, MEDICINAL RESEARCH REVIEWS, 2015, 第 6 作者
（44） Toward rapamycin analog (rapalog)-based precision cancer therapy, ACTA PHARMACOLOGICA SINICA, 2015, 第 1 作者
（45） PI3K isoform-selective inhibitors: next-generation targeted cancer therapies, ACTA PHARMACOLOGICA SINICA, 2015, 第 3 作者
（46） Identification of a Non-Gatekeeper Hotspot for Drug ResistantMutations in mTOR Kinase, CELL REPORTS, 2015, 第 4 作者
（47） Design, synthesis and biological evaluation of acylhydrazone derivatives as PI3K inhibitors, CHINESE CHEMICAL LETTERS, 2015, 第 5 作者  通讯作者
（48） 新娃儿藤碱类似物抗肿瘤作用机制研究, 2015, 第 6 作者
（49） Toward rapamycin analog (rapalog)-based precision cancer therapy, Toward rapamycin analog (rapalog)-based precision cancer therapy, 中国药理学报：英文版, 2015, 第 1 作者
（50） DW09849, a Selective Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Prevents PI3K Signaling and Preferentially Inhibits Proliferation of Cells Containing the Oncogenic Mutation p110 alpha (H1047R), JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 第 10 作者  通讯作者
（51） HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer, INTERNATIONAL JOURNAL OF CANCER, 2014, 第 9 作者  通讯作者
（52） Simultaneous targeting of PI3K delta and a PI3K delta-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia, ONCOTARGET, 2014, 第 11 作者  通讯作者
（53） Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer, CANCER LETTERS, 2014, 第 4 作者
（54） Crystal Structures of PI3K alpha Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design, ACS MEDICINAL CHEMISTRY LETTERS, 2014, 第 13 作者  通讯作者
（55） A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth, ACTA PHARMACOLOGICA SINICA, 2013, 第 5 作者
（56） Different salt derivatives of phenanthroindolizidine alkaloids display different in vitro antitumor activity, NEW JOURNAL OF CHEMISTRY, 2013, 第 6 作者
（57） Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of tumor., 2012, 第 1 作者  通讯作者
（58） Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells., JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 第 6 作者
（59） Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line, MOLECULAR AND CELLULAR BIOCHEMISTRY, 2012, 第 4 作者
（60） Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR, BIOCHEMICAL PHARMACOLOGY, 2012, 第 6 作者
（61） Discovery and bioactivity of 4-(2-arylpyrido3���,2���:3,4pyrrolo1,2-f1,2,4triazin-4-yl) morpholine derivatives as novel PI3K inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 第 7 作者  通讯作者
（62） Discovery and bioactivity of ylmorpholine derivatives as novel PI3K inhibitors., 2012, 第 1 作者  通讯作者
（63） 土槿皮乙酸减弱非转录功能的c-Jun对缺氧诱导因子1α的稳定作用, 2011, 第 3 作者
（64） Total Synthesis of 7-Ethyl-10-hydroxycamptothecin (SN38) and its Application to the Development of C18-Functionalized Camptothecin Derivatives, CHEMISTRY-A EUROPEAN JOURNAL, 2011, 第 7 作者  通讯作者
（65） 新型ATP竞争性mTOR抑制剂X-387抗肿瘤作用机制研究, 2011, 第 3 作者
（66） Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line., MOLCELLBIOCHEM, 2011, 第 1 作者  通讯作者
（67） PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo, BREAST CANCER RESEARCH AND TREATMENT, 2011, 第 9 作者  通讯作者
（68） PI3K-δ选择性抑制剂X370对白血病细胞增殖抑制作用的研究, 2011, 第 3 作者
（69） The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells, INVESTIGATIONAL NEW DRUGS, 2011, 第 5 作者
（70） A Series of alpha-Heterocyclic Carboxaldehyde Thiosemicarbazones Inhibit Topoisomerase II alpha Catalytic Activity, JOURNAL OF MEDICINAL CHEMISTRY, 2010, 第 4 作者  通讯作者
（71） Synthesis of N~(11)-anchoring biotinylated artemisinin derivatives and their preliminary biological assessment, SCIENCE CHINA-CHEMISTRY, 2010, 第 4 作者  通讯作者
（72） WJD008, a Dual Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin Inhibitor, Prevents PI3K Signaling and Inhibits the Proliferation of Transformed Cells with Oncogenic PI3K Mutant, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 第 8 作者
（73） Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells, BIOCHEMICAL PHARMACOLOGY, 2010, 第 2 作者  通讯作者
（74） Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase, BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 第 4 作者  通讯作者
（75） New microtubule-inhibiting anticancer agents, EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 第 2 作者  通讯作者
（76） 新型Src激酶抑制剂PH006的抗肿瘤作用研究, 2009, 第 3 作者
（77） S9, a novel anticancer agent, exerts its anti -proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton, CANCER RESEARCH, 2009, 第 11 作者
（78） Synthesis Study on Marmycin A: Preparation of the C3 '-Desmethyl Analogues, JOURNAL OF ORGANIC CHEMISTRY, 2009, 第 8 作者
（79） 二氢青蒿素促进癌蛋白c-MYC降解并诱发c-myc高表达的癌细胞凋亡, 2009, 第 2 作者
（80） S9, a Novel Anticancer Agent, Exerts Its Anti-Proliferative Activity by Interfering with Both PI3K-Akt-mTOR Signaling and Microtubule Cytoskeleton, PLOS ONE, 2009, 第 11 作者
（81） Direct Palladium-Catalyzed Arylations of Aryl Bromides with 2/9-Substituted Pyrimido5,4-bindolizines, JOURNAL OF COMBINATORIAL CHEMISTRY, 2009, 第 3 作者
（82） Dihydroartemisinin accelerates c-Myc oncoprotein degradation and induces apoptosis in c-Myc overexpressed tumor cells, CANCER RESEARCH, 2009, 第 2 作者
（83） 缩氨基硫脲类新化合物TSC的抗肿瘤作用及其分子机制研究, 2009, 第 3 作者
（84） Synthesis of 4-(5-Benzyl-2-phenylpyrimidin-4-yl)morpholines as Novel PI3K Inhibitors Via Acetates of Baylis-Hillman Adducts and Benzamidines, LETTERS IN ORGANIC CHEMISTRY, 2009, 第 4 作者
（85） 同时靶向PI3K/mTOR和微管的双重抑制剂的S9抗肿瘤作用, 2009, 第 11 作者
（86） Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species, CANCER BIOLOGY & THERAPY, 2008, 第 2 作者  通讯作者
（87） ADAM15 suppresses cell motility by driving integrin alpha 5 beta 1 cell surface expression via Erk inactivation, INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 第 2 作者
（88） The Marine-Derived Oligosaccharide Sulfate (MdOS), a Novel Multiple Tyrosine Kinase Inhibitor, Combats Tumor Angiogenesis both In Vitro and In Vivo, PLOS ONE, 2008, 第 3 作者
（89） 双灵固本散对DNA拓扑异构酶的抑制作用及诱导K562细胞凋亡的研究, 浙江中医杂志, 2007, 第 3 作者
（90） RNA干扰技术的研究进展, Research progresses of RNA interference, 中国药理学通报, 2007, 第 2 作者
（91） Gambogic acid inhibits the catalytic activity of human topoisomerase II alpha by binding to its ATPase domain, MOLECULAR CANCER THERAPEUTICS, 2007, 第 2 作者
（92） Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation1, ACTA PHARMACOLOGICA SINICA, 2007, 第 1 作者
（93） Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation, ACTA PHARMACOLOGICA SINICA, 2007, 第 1 作者
（94） Emerging cancer therapeutic opportunities target DNA-repair systems, TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 第 3 作者
（95） 以DNA拓扑异构酶Ⅱ为靶点的抗癌药物, Anticancer drugs targeting DNA topoisomerase II, 中国新药杂志, 2002, 第 1 作者
（96） DNA拓扑异构酶Ⅱ是salvicine作用于酿酒酵母的主要靶点, 中国药理学报：英文版, 2001, 第 1 作者
（97） 鸦胆子油乳具有多药耐药逆转和拓扑异构酶Ⅱ抑制作用, Reversal of multidrug resistance and inhibition of DNA topoisomerase ��� by emulsion of seed oil of Brucea Javanica, 中国药理学通报, 2001, 第 4 作者
（98） 螺旋藻提取物对DNA拓扑异构酶活性的抑制及对DNA的直接影响, 癌症, 2000, 第 1 作者
（99） 螺旋藻提取物对DNA拓扑异构酶活性的抑制及对DNA的直接影响, 癌症：英文版, 2000, 第 5 作者
（100） 螺旋藻提取物对表皮生长因子受体酪氨酸激酶的抑制作用及诱导hl60细胞凋亡, 癌症, 2000, 第 5 作者
（101） 拓扑异构酶Ⅱ抑制剂Salvicine导致HL-60白血病细胞DNA损伤及对c-myc表达的影响, 1999, 第 1 作者
（102） 灵芝提取物对DNA拓扑异构酶的抑制作用及诱导K562细胞凋亡, 癌症, 1999, 第 4 作者

   

（ 1 ） 新型SMARCA2降解剂的发现及其抗肺腺癌作用机制研究, 负责人, 其他, 2024-05--2025-04
（ 2 ） 组蛋白甲基转移酶EZH2介导食管鳞癌对PI3K抑制剂耐受的机制及克服策略研究, 负责人, 国家任务, 2022-01--2025-12
（ 3 ） 新PI3K抑制剂CYH33调控肿瘤免疫抗肿瘤研究, 负责人, 国家任务, 2020-01--2023-12
（ 4 ） 靶向黄嘌呤氧化酶的抗肺腺癌研究, 负责人, 国家任务, 2018-01--2021-12
（ 5 ） “个性化药物--基于疾病分子分型的普惠新药研究”个性化药物PI3Kα选择性抑制剂CYH33临床前研究, 负责人, 中国科学院计划, 2017-01--2019-12
（ 6 ） 抗肿瘤PI3Kα选择性抑制剂CYH33的临床前研究, 负责人, 地方任务, 2014-07--2017-09
（ 7 ） 靶向PI3K抗肿瘤药物耐药机制的研究, 负责人, 国家任务, 2014-01--2017-12
（ 8 ） 针对分子靶点的抗肿瘤药物发现及机理研究, 参与, 国家任务, 2014-01--2016-12
（ 9 ） mTOR催化抑制剂抗肿瘤作用机制的研究, 负责人, 国家任务, 2012-01--2015-12
（ 10 ） 基于PI3K亚型选择性抑制剂的肿瘤信号通路的研究, 负责人, 中国科学院计划, 2011-01--2013-12